AngioDynamicsANGO
ANGO
About: AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
Employees: 748
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
139% more call options, than puts
Call options by funds: $74K | Put options by funds: $31K
58% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 36
23% more capital invested
Capital invested by funds: $202M [Q2] → $250M (+$47.5M) [Q3]
1% less funds holding
Funds holding: 138 [Q2] → 137 (-1) [Q3]
5% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 22
4.41% less ownership
Funds ownership: 83.47% [Q2] → 79.06% (-4.41%) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
35%
upside
Avg. target
$13
46%
upside
High target
$14
57%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen 39% 1-year accuracy 60 / 154 met price target | 57%upside $14 | Buy Reiterated | 10 Dec 2024 |
Canaccord Genuity William Plovanic 57% 1-year accuracy 26 / 46 met price target | 35%upside $12 | Buy Maintained | 4 Oct 2024 |
Financial journalist opinion
Based on 4 articles about ANGO published over the past 30 days
Neutral
Business Wire
1 day ago
AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the second quarter of fiscal year 2025 before the market open on Wednesday, January 8, 2025, followed by a Virtual NanoKnife System investor event. Fiscal 2025 Second Quarte.
Positive
Zacks Investment Research
1 week ago
ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife
AngioDynamics' latest regulatory approval is likely to pave the way for an alternative to conventional radical surgery and improve patient outcomes.
Positive
Zacks Investment Research
1 week ago
Strength Seen in AngioDynamics (ANGO): Can Its 23.3% Jump Turn into More Strength?
AngioDynamics (ANGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Neutral
Business Wire
1 week ago
AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for the NanoKnife System for prostate tissue ablation. The Company received clearance for the NanoKnife System for prostate tissue ablation follow.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 94.32%: Here's is How to Trade
The consensus price target hints at a 94.3% upside potential for AngioDynamics (ANGO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Negative
Zacks Investment Research
1 month ago
AngioDynamics Stock Plunges 13.8% in Three Months: What's Next?
ANGO enhances its offerings and expands the breadth of its products and services. However, macro challenges are likely to continue to hurt its performance.
Negative
Zacks Investment Research
1 month ago
ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE
AngioDynamics announces the receipt of CPT Category I code for IRE technology.
Neutral
Business Wire
1 month ago
AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the launch of an international multi-center prospective registry study to assess the long term effects of treating men with unifocal intermediate-risk prostate cancer with the NanoKnife® System in partnership with t.
Neutral
Business Wire
2 months ago
AngioDynamics Announces American Medical Association's CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that IRE has received CPT® Category I codes for the treatment of lesions in the prostate and liver. The decision by the American Medical Association's (“AMA”) CPT® Editorial Panel will facilitate reimbursement for h.
Negative
Zacks Investment Research
2 months ago
AngioDynamics (ANGO) Loses -15.86% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
AngioDynamics (ANGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Charts implemented using Lightweight Charts™